IndustryCompany release
Iridex cuts 2026 revenue guidance to $46-48M after 19% third-quarter sales drop
🇺🇸 Iridex Corp (IRIX) · Tue 17 Nov 2026
The glaucoma and retinal laser maker reported weaker European and Asian demand and is reviewing its product lines while shifting manufacturing to contract manufacturers.
Iridex, a US maker of laser systems for glaucoma and retinal disease, reported third-quarter 2026 revenue of $10.2M on 17 November, down from $12.5M a year earlier. The quarter ended on 3 October, and the figures represent a fall of about 19%.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Company's press release (SEC filing): Iridex Corp ↗
Article written by VigiEye from the official source (Iridex Corp). Claims are the company's own. AI-assisted; check the source before acting.
More Industry
All →
Prenetics widens H2 EBITDA loss guidance to $30-35M as IM8 spending rises
Prenetics Global Ltd (PRE) · Wed 18 Nov 2026
Quantum-Si detects all 20 amino acids at single-molecule level on Proteus platform
🇺🇸 Quantum-Si Inc (QSI) · Wed 18 Nov 2026
NeOnc to meet FDA in January 2027 on NEO100 accelerated approval path
🇺🇸 Neonc Technologies Holdings, Inc. (NTHI) · Wed 18 Nov 2026
newcleo reports Q3 revenue of about €10M and €233.4M cash as PRECURSOR e-core completed
newcleo plc (NWCL) · Wed 18 Nov 2026
Interpace Biosciences Q3 revenue rises 18% to $10.4M on thyroid testing growth
🇺🇸 Interpace Biosciences, Inc. (IDXG) · Tue 17 Nov 2026
Viatris completes $36.50-a-share cash acquisition of Pacira BioSciences after tender offer
🇺🇸 Viatris Inc (VTRS) · Tue 17 Nov 2026